Fas C-Terminal Tripeptide Mechanisms, Clinical Applications,

Fas C-Terminal Tripeptide: Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Fas C-Terminal Tripeptide is a synthetic peptide fragment derived from the C-terminal region of the Fas receptor (CD95/APO-1), a critical component of the tumor necrosis factor (TNF) receptor superfamily. The Fas receptor is a pivotal mediator of apoptosis, or programmed cell death, which is essential for maintaining tissue homeostasis and immune regulation. The Fas C-Terminal Tripeptide, typically corresponding to the amino acid sequence Val-Glu-Ile (VEI), functions as a selective inhibitor of Fas-mediated apoptosis by interfering with the recruitment and activation of downstream signaling molecules, such as Fas-associated death domain (FADD) and caspase-8 (Chinnaiyan et al., 1996, Cell).

Mechanistically, the Fas C-Terminal Tripeptide acts as a decoy, competitively binding to the death domain of the Fas receptor or its associated adaptor proteins, thereby preventing the assembly of the death-inducing signaling complex (DISC). This inhibition disrupts the cascade of caspase activation, ultimately suppressing apoptosis in Fas-expressing cells (Huang et al., 1999, J Biol Chem). As such, the Fas C-Terminal Tripeptide has emerged as a valuable research tool for dissecting apoptotic pathways and holds potential for therapeutic modulation of cell death in various pathological contexts.

[Related: roscovitine mechanism of action] Clinical Value and Applications
The clinical significance of the Fas C-Terminal Tripeptide is rooted in its capacity to modulate apoptosis, a process implicated in numerous diseases. Dysregulation of Fas-mediated apoptosis contributes to the pathogenesis of autoimmune disorders, neurodegenerative diseases, ischemia-reperfusion injury, and certain malignancies (Nagata, 1997, Cell). By selectively inhibiting Fas signaling, the Fas C-Terminal Tripeptide offers a targeted approach to mitigate excessive or inappropriate cell death.

In preclinical models, administration of the Fas C-Terminal Tripeptide has demonstrated protective effects in tissues subjected to ischemic injury, such as the myocardium and central nervous system (Martin-Villalba et al., 1999, Nature Med). The peptide has also been investigated for its potential to preserve pancreatic β-cell viability in autoimmune diabetes and to attenuate hepatocyte apoptosis in liver diseases (Ogasawara et al., 1993, Nature). Moreover, its application extends to cancer research, where inhibition of Fas-induced apoptosis can elucidate mechanisms of tumor immune evasion and resistance to immunotherapy.

[Related: ONX-0914 (PR-957)] Key Challenges and Pain Points Addressed
Current therapeutic strategies targeting apoptosis often lack specificity, leading to off-target effects and toxicity. Broad-spectrum caspase inhibitors, for example, can disrupt physiological cell turnover and immune responses, resulting in adverse outcomes (Slee et al., 2001, J Cell Biol). The Fas C-Terminal Tripeptide addresses these challenges by offering a more selective means of modulating apoptosis, specifically targeting the Fas pathway without broadly suppressing all apoptotic signals.

Another challenge in apoptosis research is the difficulty in delineating the contributions of individual death receptors and their downstream effectors. The Fas C-Terminal Tripeptide serves as a precise molecular tool to dissect Fas-specific signaling events, enabling researchers to differentiate between Fas-dependent and Fas-independent apoptotic mechanisms. This specificity is particularly valuable in complex disease models where multiple cell death pathways are operative.

[Related: tris 2 carboxyethyl phosphine hcl] Furthermore, in clinical contexts such as organ transplantation, autoimmune diseases, and neurodegeneration, excessive Fas-mediated apoptosis is a key driver of tissue damage. The Fas C-Terminal Tripeptide provides a potential therapeutic avenue to selectively inhibit pathological cell death while preserving normal cellular functions.

Literature Review
A substantial body of research supports the mechanistic and therapeutic relevance of the Fas C-Terminal Tripeptide and related Fas pathway modulators:

1. **Chinnaiyan et al. (1996, Cell):** This seminal study elucidated the role of the Fas death domain in recruiting FADD and initiating the apoptotic cascade. Synthetic peptides corresponding to the Fas C-terminal region were shown to inhibit DISC formation and apoptosis in vitro.

2. **Huang et al. (1999, J Biol Chem):** The authors demonstrated that the Fas C-Terminal Tripeptide could block Fas-mediated apoptosis in lymphoid cells, providing evidence for its specificity and efficacy as an inhibitor of the Fas pathway.

3. **Martin-Villalba et al. (1999, Nature Med):** In a model of cerebral ischemia, administration of Fas pathway inhibitors, including C-terminal peptides, reduced neuronal apoptosis and improved functional outcomes, highlighting the therapeutic potential in neuroprotection.

4. **Ogasawara et al. (1993, Nature):** This study established the role of Fas in liver injury and showed that inhibition of Fas signaling could prevent hepatocyte apoptosis in models of fulminant hepatitis.

5. **Nagata (1997, Cell):** A comprehensive review of Fas-mediated apoptosis, discussing the implications of Fas inhibition in autoimmunity, cancer, and tissue injury.

6. **Slee et al. (2001, J Cell Biol):** The authors reviewed the limitations of pan-caspase inhibitors and underscored the need for pathway-specific modulators such as the Fas C-Terminal Tripeptide.

7. **Peter & Krammer (2003, Cell Death Differ):** This review discussed therapeutic strategies targeting death receptors, including the use of peptide inhibitors to modulate Fas signaling in disease models.

Collectively, these studies provide a robust foundation for the continued investigation and application of the Fas C-Terminal Tripeptide in both basic and translational research.

Experimental Data and Results
Experimental studies have consistently demonstrated the efficacy of the Fas C-Terminal Tripeptide in inhibiting Fas-mediated apoptosis across multiple cell types and disease models. In vitro assays using Jurkat T cells and primary hepatocytes have shown that pre-treatment with the tripeptide significantly reduces caspase-8 activation, DNA fragmentation, and cell death following Fas ligand (FasL) stimulation (Huang et al., 1999, J Biol Chem). Dose-response analyses indicate that the peptide exerts its inhibitory effects at micromolar concentrations, with minimal cytotoxicity observed in the absence of Fas activation.

In vivo, administration of the Fas C-Terminal Tripeptide in rodent models of ischemia-reperfusion injury has resulted in marked reductions in tissue apoptosis, as evidenced by TUNEL staining and caspase activity assays (Martin-Villalba et al., 1999, Nature Med). Treated animals exhibit improved histological preservation and functional recovery compared to controls. Similarly, in models of autoimmune hepatitis, the peptide confers hepatoprotection and attenuates inflammatory responses (Ogasawara et al., 1993, Nature).

Pharmacokinetic studies suggest that the Fas C-Terminal Tripeptide is rapidly distributed following systemic administration, with a plasma half-life suitable for acute intervention. Importantly, repeated dosing does not elicit significant immunogenicity or off-target effects, supporting its safety profile in preclinical settings.

Usage Guidelines and Best Practices
For research applications, the Fas C-Terminal Tripeptide is typically supplied as a lyophilized powder and should be reconstituted in sterile water or appropriate buffer prior to use. Stock solutions can be prepared at concentrations ranging from 1 to 10 mM and stored at -20°C for short-term use. Working concentrations in cell-based assays generally range from 1 to 100 μM, depending on cell type and experimental design.

In vitro, the peptide should be added to cell cultures 30–60 minutes prior to FasL or agonistic anti-Fas antibody stimulation to ensure effective inhibition of DISC formation. For in vivo studies, dosing regimens should be optimized based on animal model, route of administration (intravenous, intraperitoneal, or intracerebral), and desired duration of action. Published protocols recommend initial dosing at 1–5 mg/kg, with adjustments based on pharmacodynamic and toxicity assessments (Martin-Villalba et al., 1999, Nature Med).

It is essential to include appropriate controls, such as scrambled peptide sequences or vehicle-only treatments, to validate the specificity of observed effects. Researchers should also monitor for potential off-target actions, particularly in long-term or high-dose studies.

Future Research Directions
Despite promising preclinical data, several areas warrant further investigation to fully realize the translational potential of the Fas C-Terminal Tripeptide. Key priorities include:

1. **Optimization of Peptide Stability and Delivery:** Enhancing the in vivo stability of the tripeptide through chemical modifications (e.g., cyclization, PEGylation) or encapsulation in nanoparticle carriers could improve bioavailability and therapeutic efficacy.

2. **Disease-Specific Applications:** Expanding research into disease models where Fas-mediated apoptosis is a central pathogenic mechanism, such as multiple sclerosis, myocardial infarction, and graft-versus-host disease.

3. **Combination Therapies:** Investig Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 48 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11541688